Open AccessEfficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy
Author(s) -
D. Prieto-Peña,
Monica Calderón-Goercke,
Alfredo Adán,
Lillian Chamorro-López,
Olga MaízAlonso,
Juan R De Dios-Jiménez Aberásturi,
Raúl Veroz,
S. Cantero Blanco,
J.M. Martín-Santos,
Francisco Navarro,
A. Gallego,
Senén González-Suárez,
Arantxa Conesa,
A. García-Valle,
Miguel CorderoComa,
Nieves Pardiñas-Barón,
Rosalía Demetrio,
V. Calvo-Río,
Víctor MartínezTaboada,
Santos Castañeda,
José L. Hernández,
Miguel A. GonzálezGay,
R. Blanco
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/j9ysbm
Subject(s) - medicine , certolizumab pegol , uveitis , pregnancy , pediatrics , obstetrics , adalimumab , rheumatoid arthritis , ophthalmology , genetics , biology
Clinicians often face the challenge of providing effective and safe therapy for pregnant women with uveitis. Certolizumab pegol (CZP) differs from other anti-TNFα agents due to its limited placental transfer. In this study we assessed the efficacy of CZP in pregnant women with uveitis. We also provided information on outcomes of pregnant women and neonates exposed to CZP.